Quarterly ResultJul 15, 2026, 07:56 AM
Johnson & Johnson Q2 Sales $25.3B, EPS $2.90; Raises 2026 Outlook
AI Summary
Johnson & Johnson reported strong second-quarter 2026 results, with reported sales increasing 6.6% to $25.3 billion and adjusted EPS rising 4.7% to $2.90. The company raised its full-year 2026 guidance, now expecting reported sales of $101.1 billion and adjusted EPS of $11.68 at the midpoint. This performance was driven by robust growth in both the Innovative Medicine and MedTech segments, alongside significant innovation with multiple product approvals and pipeline advancements.
Key Highlights
- Q2 2026 reported sales grew 6.6% to $25.3 billion.
- Q2 2026 adjusted EPS was $2.90, an increase of 4.7%.
- Raised 2026 estimated reported sales guidance to $101.1 billion (midpoint).
- Raised 2026 adjusted EPS guidance to $11.68 (midpoint).
- Innovative Medicine worldwide operational sales grew 6.8%.
- MedTech worldwide operational sales grew 3.6%.
- Received approvals for TREMFYA, CAPLYTA, and Dual Energy THERMOCOOL SMARTTOUCH SF platform.
- Advanced pipeline with data from RYBREVANT FASPRO, TALVEY plus DARZALEX FASPRO, and OTTAVA.
Price Impact
More from JNJ